Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1

Conditions

Stomatitis 10Multiple Myeloma 9Lymphoma, Non-Hodgkin 9Lymphoma 9Hodgkin Disease 9Leukemia, Myeloid, Acute 8Leukemia 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Neoplasms 7Mucositis 6Myelodysplastic Syndromes 5Lymphoma, Large B-Cell, Diffuse 5Head and Neck Neoplasms 5Neoplasms, Plasma Cell 4Leukemia, Lymphocytic, Chronic, B-Cell 4Recurrence 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Hematologic Neoplasms 3Burkitt Lymphoma 3Blast Crisis 3Radiation Injuries 2Lymphoma, T-Cell 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Graft vs Host Disease 2Drug-Related Side Effects and Adverse Reactions 2

Interventions

Cyclophosphamide 151Dexamethasone 140Rituximab 83fludarabine 78Cytarabine 69Lenalidomide 68Bortezomib 63fludarabine phosphate 62Gemcitabine 62venetoclax 54Etoposide 53pembrolizumab 52pomalidomide 48Paclitaxel 48Cisplatin 47Carboplatin 47Peripheral Blood Stem Cell Transplantation 46Filgrastim 40Radiotherapy 39Calcium Dobesilate 36Busulfan 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 29Vincristine 28Temozolomide 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Recurrence × Fibroblast Growth Factor 7 × Clear all
NCT01200329 2019-12-16

High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease

M.D. Anderson Cancer Center

Phase 2 Completed
81 enrolled 8 charts
Lymphoid

Hodgkin Disease, Lymphoma, Recurrence

NCT01421173 2015-11-18

Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies

M.D. Anderson Cancer Center

Phase 1 Completed
78 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Recurrence

NCT02114502 2014-07-11

Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡